International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 03 March 2024

Page No: 475-483

DOI: https://doi.org/10.47191/ijmscrs/v4-i03-20, Impact Factor: 7.949

The Impact of Advanced Reproductive Medicine on Female Fertility: Clinical and Technological Perspectives

Bolívar Leonardo Saquinga Pujos*[1], Alex David Noroña Pilataxi[2], Jamie Patricia Celi Andrade[3], Michael Roberto Flores[4], Ginger Vanessa Miranda Alburquerque[5], Miriam Elizabeth Tierra Vargas[6]

[1] Physician, Hospital General Santo Domingo. Master´s Degree in Occupational Medicine, ORCID: 0000-0002-3251-7122

[2] Physician, Centro de Salud tipo "C" Latacunga, ORCID: 0009-0003-9318-213X

[3] Physician, Universidad estatal de Guayaquil, Centro de salud tipo "C", Ciudad Victoria, ORCID: 0009-0003-9384-6450

[4] Physician, Universidad estatal de Guayaquil, Centro de salud tipo "C", Ciudad Victoria, ORCID: 0009-0003-3842-997X

[5] Obstetrician, Universidad de Guayaquil, ORCID: 0009-0005-4498-4886

[6] Obstetrician, Universidad de Guayaquil, ORCID: 0009-0008-9031-5028

ABSTRACT

Background: Infertility is defined as failure to be pregnant after 12 months of unprotected intercourse. This condition affects millions of individuals worldwide. It is not only a personal problem, causing stress and anxiety amongst individuals and couples, but it has become a community issue. One in every 6 couples will experience infertility in their lifetime. It is affecting both male and female reproductive systems, with causes ranging from hormonal imbalances to obstructive disorders. Despite its prevalence, fertility care is unequal and, for those in low and middle-income countries, virtually non-existent and a long overdue topic for global attention and action.

Method: We followed a systematic approach to select articles related to recent developments in female fertility and reproductive medicine. Keywords such as "female fertility" and "advanced reproductive medicine" were used for getting targeted articles. We used only peer-reviewed articles published from 2019 to 2024. Only high-quality data was extracted for general public information.

Result: Our findings show that Assisted Reproductive Technologies (ART), microfluidic devices, and innovations like CoQ10 therapies have significantly improved fertility treatment outcomes. AI-driven personalized medicine has enhanced accessibility and effectiveness, democratizing fertility care. Stem cell therapy and platelet-rich plasma techniques are another breakthrough in reproductive medicine.

Conclusion: It is concluded that medical advancements have revolutionized reproductive medicine. There is now a ray of new hope for those couple who are experiencing infertility. The future promises further improvements in success rates and patient experience with continued progress.

KEYWORDS: Reproductive medicine, female fertility

ARTICLE DETAILS

Published On:
13 March 2024

Available on:
https://ijmscr.org/

I. INTRODUCTION

(Infertility affects approximately one in six couples globally, delineated as the inability to achieve a successful pregnancy after one year of unprotected sexual intercourse. While infertility can stem from various factors, roughly 50% of cases are attributed to female-related issues [1]. Female infertility encompasses a spectrum of disorders, including ovulation irregularities, fallopian tube damage (tubal infertility), cervical abnormalities (such as benign polyps or tumors and cervical stenosis), and hormonal imbalances [1]Among the hormonal conditions implicated in female infertility are polycystic ovary syndrome (PCOS), endometriosis, premature ovarian failure (POF), hypothalamic dysfunction, hyperprolactinemia (characterized by excessive prolactin production), uterine fibroids, and pelvic inflammatory disease (PID) [2].

An array of risk factors exacerbates the likelihood of infertility in women. These include tobacco use, excessive alcohol consumption, exposure to chemotherapy or radiation therapy, prolonged use of high-dosage nonsteroidal anti-inflammatory drugs (NSAIDs) [3]. intake of antipsychotic medications, use of recreational drugs such as marijuana and cocaine, obesity, advancing age, and sexually transmitted infections (STIs) [4].

There are 2 main categories associated with infertility: Physical disorders and psychosocial challenges. Physical manifestations of this condition encompass menstrual irregularities (including absence, irregularity, or pain), changes in skin texture, fluctuations in libido, excessive hair growth in atypical areas (such as the lips, chest, and chin), and weight fluctuations. On the other hand, psychosocial implications include difficulties in interpersonal relationships, diminished self-esteem, feelings of shame, social withdrawal, and heightened risk of mental health disorders (such as depression, anxiety, despair, guilt, and worthlessness) [5].

Fortunately, contemporary advancements in medical science offer a range of therapies enabling women to conceive. These include ovulation-inducing medications like clomiphene and gonadotrophins, assisted reproductive technologies (such as in vitro fertilization (IVF) and intrauterine insemination (IUI)), as well as options like egg and sperm donation. Additionally, interventions such as ovulation induction and micronutrient supplementation have opened doors for infertile women to realize their dreams of parenthood. This paper aims to discuss the latest advancements in reproductive health among males and females who cannot get pregnant. In this review, we will discuss clinical and technological innovations such as Assisted Reproductive Technologies (ART), including In vitro fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), and Preimplantation Genetic Testing (PGT), emerging technologies such as Ovarian Tissue Cryopreservation, Ovarian Rejuvenation Therapies, stem cell and platelet rich plasma therapies, and Artificial Ovaries, personalized and precision approaches. We discuss how these technologies have changed the lives of millions of people around the globe [6].

II. METHODOLOGY

Systematic Approach: We decided to follow a careful, systematic approach, ensuring thorough and unbiased study selection; specifically, those studies discussing the latest and novel advancements in reproductive technology were selected. We followed proper search strategies and decided to run the research on Scopus, Web on Science, and PubMed. We established predefined inclusion and exclusion criteria with proper screening processes to identify and include high-quality literature.

Keyword Selection: Our main keywords will include advanced reproductive medicine, female fertility, assisted reproductive technologies, in vitro fertilization, ovarian rejuvenation, and preimplantation genetic testing. We also used some secondary keywords like Clinical and Technological Perspectives, female infertility, advanced reproductive medicine, clinical perspectives, technological advancements, Assisted reproductive technologies (ART), fertility treatment outcomes, microfluidic devices, CoQ10 therapies, personalized medicine, and accessibility in fertility care. All these primary and secondary keywords were combined, and we used Boolean operators AND, OR, and NOT to make appropriate Mesh terms to cover data of interest.

Inclusion Criteria: Before selecting studies after screening, predefined inclusion criteria were kept in mind. The articles were filtered (from 2019 to 2024) to keep the study current to include only English language and human studies. We prioritized selecting papers from journals, reviews, and other peer-reviewed publications. We included only studies focusing on innovations in reproductive medicine relevant to female fertility.

Exclusion Criteria: All the other studies that do not meet our predefined criteria, unpublished papers, grey literature, and papers containing relevant information were excluded.

Selection of Articles: A systematic literature was conducted using academic databases such as PubMed, Scopus, and Web of Science. On these databases, the total results were 1796; out of these, 550 duplicates were removed, 4 records were marked ineligible for automation tools, and 17 other studies were removed for other reasons. A total of 1225 papers were screened for their title and abstract; out of this, 960 papers were removed. After 265 full-body papers were studied, a final selection of 30 articles meeting all inclusion criteria was included in the review.



Figure 1. PRISMA Flowchart

III. RESULTS

Traditional Reproductive Medicine Techniques

In ancient civilizations such as the Vedic era, methods like Niyoga paratha and artificial insemination were known, and these procedures show that people have had an awareness of assisted conception and gamete manipulation. Niyoga paratha was a practice used by ancients where a woman was allowed to conceive with a man other than her husband so that they may get pregnant. Artificial insemination, was a process that involved manually introducing semen into a woman's reproductive tract. In old times, infertility was often perceived as a personal failure, particularly for women, and this idea still exists in uncivilized and illiterate societies around the world, which leads to societal stigma and various coping mechanisms, including polygamous marriages [7].

From the Renaissance period onward, scientific progress influenced infertility treatment. The shift from superstition to rational medical thinking led to the recognition of infertility as a medical issue. Hippocrates pioneered early therapeutic approaches focusing on lifestyle changes. Modern scientific exploration, marked by Antonie Philips van Leeuwenhoek's discovery of spermatozoa in 1677, has since led to a deeper understanding of reproductive physiology and the development of pharmacological and surgical interventions to address infertility. Research stated that about 85 to 90% of infertility is treated with traditionally used medical therapies such as surgeries and medicines [8].

The modern scientific perspective on infertility treatment has evolved from the Renaissance period to the present day, marked by significant advancements in medical understanding and technology. Ancient Greek medicine, initially rooted in superstition and religion, gradually transitioned to evidence-based practices, with Hippocrates pioneering rational medical thinking. Hippocratic therapies primarily focused on lifestyle changes for infertility treatment [9].

The development of infertility treatment techniques gained momentum with scientific inquiry into the causes of infertility. In 1677, Antonie Philips van Leeuwenhoek's discovery of spermatozoa paved the way for understanding reproductive physiology. Subsequent discoveries, such as Lazzaro Spallanzani's demonstration of sperm's essential role in fertilization, led to advancements like artificial insemination (AI). AI techniques evolved over time, culminating in the birth of the first test tube baby in 1978 through in vitro fertilization (IVF) [9].

Traditional infertility treatments like artificial insemination, AI, and IVF are challenging because these are expensive and less effective and cause emotional stress and physical discomfort. These procedures have variable success rates and have health risks. To overcome these demands, continued research upon technological advancement and ethical considerations to ensure the safety, effectiveness, and accessibility of reproductive medicine.

Innovations in Assisted Reproductive Technologies (ART)

Assisted Reproductive Technologies (ART) are medical procedures that help people conceive when they face fertility issues. Most of these treatments involve the manipulation of an egg or embryo to increase the chances of pregnancy; however, procedures, such as intrauterine insemination (IUI), which is basically just placing sperm inside the uterus is excluded form ART process because it include more complicated processes like ICSI or IVF [10]. The first successful in vitro fertilization (IVF) treatment in humans was actually carried out in 1978 in England. The woman's egg was removed from her ovary, fertilized by sperm outside her body and then returned to her uterus to grow. Since that time, IVF has quickly spread across the world, providing hope to millions dealing with infertility [10].

In Vitro Fertilization in ART

In vitro fertilization (IVF) is the most commonly utilized Assisted Reproductive Technology ART. IVF process begins by stimulating the ovaries to produce multiple eggs — typically with hormone medications — to increase the likelihood of collecting viable eggs available for fertilization. After the eggs mature, they are removed from the ovaries in a quick and minimally invasive procedure that is guided by ultrasound. The biological specimens (retrieved eggs) are then combined with sperm in the laboratory using either conventional fertilization or intracytoplasmic sperm injection (ICSI) in the setting of the male factor. After fertilization, the resulting embryos are cultured outside for a few days to promote development. The embryo that is developed is then placed in the woman's uterus to carry on their development and grow. Only one embryo is carefully chosen to lessen the risk of multiple babies start developing at one time. More advanced methods including PGT (pre-implantation genetic testing) and embryo cryopreservation may be combined to improve one's chances of success. However, although ART concessions are available for some couples but expect great difficulty involving infertility and/or associated physical irregularity with past surgery for example it is an ambitious, risky enterprise as well [10]. Infertile-related disorders, Destructive medical treatment of the ovaries in earlier years and other serious obstacles to reproductive health found in modern times requires us to take advantage of the benefits available from ART (Assisted Reproductive Technique). Information from the Centers for Disease Control reports that in 2017, 1.9% of infants born in the United States were conceived using ART. That year, approximately 200,000 ART cycles resulted in 78,052 live births, highlighting the increasing use of ART. With expanding access, delayed childbearing trends, and broader insurance coverage for ART, these numbers are likely to continue to rise. Thus, women's health and reproductive healthcare providers must have a fundamental understanding of ART indications and an appropriate timeline for referral to reproductive endocrinology and infertility specialists [10].

Table 1: Cutting edge technologies and innovations to revolutionize IVF

Advancement	Explanation
Preimplantation Genetic Testing (PGT)	PGT allows for the screening of embryos to identify genetic abnormalities before implantation, increasing the chances of a successful pregnancy by selecting healthy embryos.
Time-lapse Embryo Imaging	Continuous monitoring of embryo development using noninvasive time-lapse technology allows for better embryo selection based on growth patterns and milestones, improving IVF success rates.
Artificial Intelligence (AI) & Machine Learning	AI and machine learning analyze patient data and embryonic development to provide personalized treatment recommendations, optimizing IVF outcomes.
Ovarian Tissue Cryopreservation	This technology enables the freezing and preservation of ovarian tissue, containing viable eggs, for women undergoing cancer treatment or other medical procedures that may affect fertility.
Improved Culture Media	IVF culture media containing key components such as polyvinylpyrrolidone (PVP), hyaluronic acid (HA), and buffer solutions. These substances, utilized in both sequential and single-step media formulations, create optimal environments for embryo development, enhancing the success rates of IVF procedures.
Egg Freezing Techniques	Vitrification is a rapid freezing method. This method has improved egg-freezing success rates without damaging oocyte while cryopreservation, giving women more options for preserving their fertility.
Single Elective Embryo Transfer (eSET)	eSET is reducing the risk of multiple pregnancies. eSET involves transferring a single carefully selected embryo, maintaining high success rates while minimizing complications ¡Error! No se encuentra el origen de la referencia..

Intracytoplasmic Sperm Injection (ICSI)

The ICSI was first introduced in 1990s, for the first time, it was possible to achieve fertilization with a single sperm. In this Technique, ICSI is injected directly into the oocytes and it is allowed to be fertilized and turn into an embryo. Since then, ICSI has emerged as a cornerstone of IVF.

Critics argue that ICSI can facilitate the transmission of genetic abnormalities and also rise ethical concerns. It is believed to cause such as autosomal recessive mutations, and raise the risk of imprinting disorders in offspring. Beside these complications, ICSI remains an invaluable tool in assisted reproduction and is being used successfully [12].

Coenzyme Q10 Supplementation and ICSI

Supplementation with Coenzyme Q10 (CoQ10) is promising way to improve oocyte quality particularly in older women. With powerful antioxidant properties and a key role in cellular energy production, CoQ10 has promised to mitigate the age-related decline in ovarian function. There are various previous researches on animal models have shown that CoQ10 supplementation was able to maintain ovarian reserve, improve mitochondrial function, and reduce oocyte aneuploidy. Concerns about the long-term safety and efficacy of CoQ10 supplementation needs investigation so more research is needed. CoQ10 is non-invasive and potentially cost-effective strategy for improving IVF outcomes [13].

Microfluidics in IVF Laboratory Automation in ICSI

Much like microarray tools have automated genome analysis, microfluidics technology is on the brink of automating the embryology laboratory, allowing for complete control over gamete and embryo manipulation within a microsystem. Microfluidic devices exploit fluid dynamics and surface forces to sort sperm with high efficiency, culture embryos with minimal evaporation loss, and perform genetic assays [14]. This not only has promise for standardizing IVF procedures and reducing the variability seen using manual droplet techniques, but it also allows for moving all procedures between programmed times with no technologist intervention. While microfluidics shows promise in improving efficiency, throughput, and standardization of IVF procedures, there is much development still needed. These tools, similar to other assisted reproductive technology treatments that are currently being developed, will need to be scaled up from the research prototype and miniaturized, yet at the same time integrated into systems for eventual clinical use. The nature of microfluidic systems is in some ways a positive, obviating the need for a technologist to manipulate embryos directly, but is also a potential regulatory hurdle in convincing agencies such as the FDA that such a system, in fact, improves current pregnancy rates to such a degree that different or fewer clinical trials will be needed to gain approval [14].

Table 2: Advancements in AI and Robotics in ICSI

Advancement	Description
Computer and AI-based algorithms for semen analysis	AI algorithms are being used for various parameters of semen quality, such as sperm morphology, motility, and DNA integrity. They provide objective analysis and selection of the best sperm cells.
Artificial intelligence-based predictive algorithms for patients with affected fertility	AI algorithms aids improving sperm identification process in patients with conditions like nonobstructive azoospermia (NOA). Since the use of AI has come, it has enhanced success of microsurgical testicular sperm extraction (micro-TESE) procedures.
Current state of AI-based algorithms for real-time tracking of single-sperm during ICSI	AI algorithms are being developed for real-time tracking and selection of single sperm during intracytoplasmic sperm injection (ICSI) to prevent multiple pregnancies. AI has become able to analyze individual sperm characteristics in high-magnification images or videos, facilitating the precise selection of sperm for fertilization.
Size and Bias of Datasets	The effectiveness of AI algorithms in sperm selection depends on the size and quality of datasets used for training. Studies highlight the need for large, diverse datasets to improve predictive power and performance across heterogeneous patient populations.
Use of Unsupervised Training Models	AI models can employ supervised or unsupervised learning approaches. While supervised models are trained with labeled data, unsupervised models detect patterns in unlabeled data. Both approaches offer their benefits in optimizing AI algorithms for sperm selection during ICSI ¡Error! No se encuentra el origen de la referencia..

Emerging Technologies in Reproductive Medicine

Ovarian Tissue Cryopreservation

Every year, a significant number of women under 45 are diagnosed with cancer. Moreover, while modern medical techniques keep the tumor at bay, for many, ovarian damage and infertility are the price they must pay for survival. The current preservation techniques also serve as moribund water stands for prepubescent girls and those in dire need of chemotherapy treatment. OTC-T not only may portend fertility restoration, but it is also the recognized system of value for cancer-suffering prepubescent patients. In recent studies, more than 95% of women showed lasting ovarian function after having undergone OTC. New techniques keep the prospect alive as one that you will live to see become a reality: OTC-T is gradually established as a recognized fertility preservation operation by leading societies of reproduction medicine [16].

Moreover, despite considerable concerns regarding the possibility of malignancy contamination, the few reported cases have been isolated and remote, further indicating its considerable worth and high safety record. Despite a material improvement in chances of survival with chemotherapy and radiation treatments, there is usually a risk of damage to the ovaries. Understanding the mechanisms by which cancer treatment causes ovarian toxicity is critical for designing effective preservation techniques. Recent studies: Unraveling the pathways leading to follicular loss post-transplantation offers insights for OTC-T [16]. Preservation of fertility for young women who have cancer is fast becoming an increasingly important question today. However, with ovarian tissue cryopreservation and transplantation, there can be a light of hope. It dramatically improves people's lives after survival. Continued research and development in this area will further increase how well we can protect women's reproductive environment while under attack due to a cancer diagnosis [16].

Ovarian Tissue Cryopreservation Techniques

Slow freezing involves controlled freezing of ovarian tissue to -140°C, then storage at -196°C, posing a risk of ice crystal formation. Vitrification instantaneously solidifies tissue using high cryoprotectant concentrations, minimizing ice crystal formation. Vitrification is faster, with less tissue damage, but slow freezing offers superior AMH production and may be more suitable for long-term storage [17].

Table 3: Comparison of OTC Techniques: Slow Freezing vs Vitrification

Criteria	Slow Freezing	Vitrification
Freezing Process	Frozen slowly in a controlled manner down to -140°C, then stored at -196°C in liquid nitrogen	Involves instantaneous solidification of the solution with high concentration of cryoprotectant agents
Risk of Tissue Damage	Risk of ice crystal formation causing mechanical damage to cells	Low risk of ice crystal formation
Handling Time	Longer handling time	Reduced handling time
Equipment Cost	May require expensive equipment	Inexpensive equipment
Preservation Efficacy	Mixed findings; better preservation of stromal cells but greater damage to follicles in some studies	Mixed findings; some studies report greater damage to follicles compared to slow freezing
AMH Production	Superior AMH production observed in tissue cultures after slow freezing	Efficiency in AMH production not as well established
Conception Rates	Limited success rates reported following vitrification	Limited data on conception rates following vitrification
Fragmentation Issues	Larger sample size required, potential hindrance in long-term cryo-storage and surgical procedures	Smaller fragments may increase handling steps, prolonging freezing process and increasing risk of toxicity ¡Error! No se encuentra el origen de la referencia.

Patient Age and Predictive Factors

Age emerges as a critical factor influencing the success of OTC, with primordial follicle preservation being paramount. Typically, individuals under 35 years old are considered optimal candidates due to the decline in follicle numbers with age. Predictive markers like anti-Müllerian hormone (AMH) levels and antral follicle count aid in assessing ovarian reserve, providing valuable insights into future pregnancy prospects [19].

Cryoprotectants and Vitrification Protocols

Many different cryoprotectants, such as ethylene glycol, dimethyl sulfoxide (DMSO), and Propanediol, are used in OTC, while Vit ___ protocols yield differing grades of efficacy. Current tasks include attempting to optimize combinations of cryoprotectants and variations in concentrations in the hope of achieving maximum follicle survival rates after thawing. Experiments have shown a complex interplay between cryoprotectants, blood vessel generation, and cell growth after transplantation of ovarian tissue. This demands further exploration for purposes of protocol refinement [20].

Anti-apoptotic Agents and AMH: In OTC, the prevention of apoptosis and the maintenance of improved follicle survival are high priorities. Anti-apoptotic substances like Sphingosine-1-phosphate (S1P) and ceramide inhibitors offer prospects of protecting follicles. Moreover, AMH not only emerges as an index of ovarian reserve but also acts to inhibit all cyclic recruitment of primordial follicles. Administration of AMH to chemotherapy agents has the potential to preserve ovarian function during gonadotoxic treatments [21].

Innovative Cooling Techniques

Such as Slush Nitrogen (SN) offers enhanced cooling rates because, unlike traditional ways, it has no limits.SN, symbolic of these new techniques, has led to better vitrification results by necessitating less exposure time for cryoprotectants and protecting the integrity of cells once thawed out. Laser-assisted thawing techniques display higher survival rates for oocytes and embryos. These results reveal that proper methods for warming are as crucial to successful vitrification as anything else [22].

Mitigating Cancer Cell Re-implantation Risks

Contamination of ovarian tissue with cancer cells is a significant headache for OTC. Strategies aimed at in vitro maturation (IVM) of oocytes and meticulous checking of tissue samples To preclude such contamination Before transplantation are being developed. Treatments before transplants involving malignant cells show promise in reducing the frequency of re-implantation of cancer cells. This offers new hope for qualifications made in cancer patients ' fertility [23].

Surgical techniques for transplantation of the ovarian tissue

As the vital force behind fertility preservation among cancer patients, surgical techniques play a crucial role in ovarian tissue transplantation (OTT)-usually done without coagulation to ensure surgical specimens can cultivate eggs and eventually have kids. You must figure out the amount of tissue to remove the operation tools required in the way of suitable volume contexts, considering such factors as age and history of chemotherapy. Regarding transplant sites and methods, it depends on one's remaining ovary as a recipient or using heterotopic procedures [23]. Generally speaking, orthotopic transplantation is preferred. Advances in surgical technique continue to produce better results, raising fresh hope for successful fertility retention in these patients. Therapy for Ovarian Rejuvenation. Therapies for ovarian rejuvenation attempt to address female infertility by rejuvenating or restoring ovarian function using new technology. These technologies are especially relevant to women with age-related infertility and premature ovarian insufficiency. Although the means remain primarily experimental, several methods have been tried to boost ovarian function and improve the chances of fertility [23].

Stem cell therapy

Stem cell therapy is a new kind of regenerative medicine that becomes especially suitable for treating different illnesses by harnessing the unique properties of stem cells. With the deepening of research, the application of stem cell therapy in the treatment of ovarian dysfunction has been increasingly explored, particularly in diseases such as premature ovarian insufficiency (POI). Characterized by the loss of ovarian function before the age of 40, POI poses excellent difficulties to women's reproductive health, often leading to infertility and difficulties related to hormonal balance. Stem cells are divided into pluripotent and multipotent categories according to their potential for differentiation. Pluripotent stem cells--such as embryonic stem cells (ESCs)--can differentiate into tissues derived from all three germ layers, yet ethical concerns and the potential for tumor formation restrict them [24].

Conversely, induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) represent alternative sources of pluripotent and multipotent stem cells, respectively: iPSCs are obtained through cellular reprogramming, whereas MSCs come from adult tissues such as bone marrow, fat or umbilical cord [25]. The therapeutic potential of stem cells in ovarian dysfunction has been explored extensively through preclinical studies using various animal models, including chemically-induced ovarian failure models, naturally aged models, and genetically modified mice. In this research, attention is being directed toward the effectiveness of different stem cell therapies for restoring ovarian function, helping follicles to grow, and dealing with infertility associated with POI. Nevertheless, it is still difficult to compare the results from animal studies as there are differences among the animal models themselves and between animal physiology and human pathology. As well as carrying out trials on animals for preclinical research, several clinical trials and pending projects are currently underway to investigate the possibility and safety of stem cell therapies for ovarian dysfunction in human patients. These investigations should shed some light on developing stem cell-based treatments that aim to improve ovarian function and deal with reproductive disorders [26].

Table 4: latest innovations in ovarian Rejuvenation

Innovation	Description
Induced Pluripotent Stem Cells (iPSCs)	Generated from patient-derived cells and differentiated into ovarian cells, such as oocytes and granulosa cells. Used for disease modeling, drug screening, and potentially generating patient-specific cell therapies for conditions like Premature Ovarian Insufficiency (POI) .
CRISPR/Cas9 Gene Editing	Enables precise editing of the genome to correct genetic mutations associated with ovarian disorders or infertility. Investigated for correcting mutations in patient-derived iPSCs or engineering ovarian cells with enhanced therapeutic properties ¡Error! No se encuentra el origen de la referencia..
Exosome Therapy	Utilizes exosomes secreted by stem cells containing bioactive molecules to modulate ovarian function. Potential non-invasive approach for delivering therapeutic cargo to the ovaries, promoting follicular growth, and protecting against ovarian damage.
Biomaterial-Based Approaches	Utilizes hydrogels and scaffolds to create microenvironments conducive to ovarian cell growth and function. Enhances survival and integration of transplanted ovarian cells, supporting their therapeutic effects in treating ovarian disorders or infertility.
Microfluidic Systems	Allows precise control of cellular microenvironments critical for studying ovarian follicle development and hormone regulation. Used to model interactions between ovarian cells and their environment, providing insights into ovarian physiology and disease mechanisms ¡Error! No se encuentra el origen de la referencia..

Ovarian PRP

Ovarian PRP is a type of ovarian rejuvenation therapy that uses platelet-rich plasma derived from a woman's blood to enhance ovarian function and fertility outcomes. Cellular rejuvenation becomes stimulated, and so does ovarian blood flow. PRP promotes the growth and maturation of healthy eggs; PRP offers potential applications in treating conditions such as diminished ovarian reserve and primary ovarian insufficiency [29].

Artificial ovaries

With the advent of artificial ovaries, it should be possible to offer young women the chance to have children after undergoing treatment for cancer or because they suffer from idiopathic premature ovarian insufficiency--a still inscrutable phenomenon that occurs in 1 out of 100 menopausal women. Artificial ovaries involve replicating natural ovarian functions, including oocyte production and hormone secretion--so they differ significantly from traditional approaches to vitrification. But challenges remain. They include trying to guarantee safety, choosing a matrix material that permits the various adornments laypeople would want on any such next-generation medical device, addressing ethical issues-- such as equitable access or genetic modification--and the need to keep costs down enough for widespread use. Continuing research is also looking at alternative sources for oocytes, such as induced pluripotent stem cells (iPSCs) and new versions of the old-fashioned ovary-yielding ovum. Work on 3D printed ovary scaffolds progresses apace. Despite the difficulties, artificial ovaries may offer promise for the future--though further research and ethical considerations will be necessary if their full benefit is to be realized [30].

Personalized Medicine

Personalized medicine's progress in many ways has meant infertility treatments are tailored. By using an individual's genetic, protein, or metabolite profile, our tools can personalize protection strategies and frequently profit from extensive follow-ups to determine their effectiveness. With genomic, transcriptomic, and proteomic biomarker-steered diagnostics, prognosis, and treatment decisions, in vitro fertilization cycles can all be made more effective. From discerning the genetic basis of premature ovarian failure to gauging endometrial receptivity or refining ovarian hyperstimulation strategies, personalized medicine has dramatically increased the potency and individualization of assisted reproduction techniques. By bringing together the latest technology and predictive models, practitioners are able to provide treatments narrowly targeted at particular patient groups, thereby reducing risks and increasing success rates. Revolutionary as it is now, this change will see a future in which reproductive medicine adopts an entirely new form.

Advancements in AI and Data Science Applications in Reproductive Health

Medicine and reproductive health have been altered forever by the latest developments in artificial intelligence (AI) and data science that were fueled prominently as deep neural networks confirm it. Large-scale genomic datasets can be scoured for predictive genetic variants and deep neural networks conceived treatments. As deep neural networks generate their pathways for detectives, they have increased genetic medicine from the genomic level to much larger databases of medical images such as ImageNet. AI expands such "precision" medicine beyond genetics. In reproductive health, AI assists in carrier genetic screening, preimplantation genetic testing, embryo selection, and noninvasive prenatal testing, which detects genetic abnormalities. The challenges of bioethics encompass standardization, biased predictions derived from widely divergent training datasets, restricted data sharing, and integration with established working patterns [15].

IV. CONCLUSIONS

From all the above research, we can conclude that the latest innovations in reproductive medicines, such as Assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and other innovative strategies such as ovarian tissue cryopreservation (OTC) and vitrification, have revolutionized the treatment of fertility. We discussed novelties like slow freezing and vitrification, which have enhanced the preservation of gametes and embryos without damaging the embryos, providing maximal success rates. Microfluidic devices have also been launched in IVF laboratories, which have enabled more precise embryo culture conditions and promoted embryo development and implantation potentials.

We can conclude that coenzyme Q10 (CoQ10) and ovarian rejuvenation therapies offer promising approaches to improving ovarian function and egg quality, addressing age-related infertility. Stem cell research and artificial ovaries are strategies that will help us restore fertility in individuals with ovarian insufficiency or damage. Artificial intelligence (AI) is now being used at every step of these technologies, which has made things easier to handle and minimize risks. All these advancements are the latest breakthroughs of the modern era that have offered new avenues to solve infertility among people who want kids. As technology and AI use continue evolving, the future of reproductive medicine will be more promising with improved success rates.

REFERENCES

I. World Health Organization: WHO. Infertility [Internet]. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/infertility

II. Walker MH, Tobler KJ. Female infertility [Internet]. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556033/

III. News-Medical. The Effect of Anti-Inflammatories on ovulation [Internet]. News-Medical. 2022. Available from: https://www.news-medical.net/health/The-Effect-of-Anti-Inflammatories-on-Ovulation.aspx

IV. Emokpae MA, Brown SI. Effects of lifestyle factors on fertility: practical recommendations for modification. Reproduction & Fertility [Internet]. 2021 Jan 8;2(1):R13–26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812443/

V. Sharma A, Shrivastava D. Psychological problems related to infertility. Cureus [Internet]. 2022 Oct 15; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661871/

VI. Fertility drugs [Internet]. WebMD. 2000. Available from: https://www.webmd.com/infertility-and-reproduction/fertility-drugs

VII. Mohapatra R, Dash SK, Padhy S. Ethnobiological Studies from Manusmruti: IX. Niyoga Prathaa, A Natural Process of Artificial Insemination. Journal of Human Ecology [Internet]. 2001 Jan 1;12(1):33–8. Available from: https://www.researchgate.net/publication/321201780_Ethnobiological_Studies_from_Manusmruti_IX_Niyoga_Prathaa_A_Natural_Process_of_Artificial_Insemination

VIII. What infertility treatments are available? [Internet]. https://www.nichd.nih.gov/. 2017. Available from: https://www.nichd.nih.gov/health/topics/infertility/conditioninfo/treatments#f1

IX. Sharma RS, Saxena R, Singh R. Infertility & assisted reproduction: A historical & modern scientific perspective. DOAJ (DOAJ: Directory of Open Access Journals) [Internet]. 2018 Dec 1;148(Suppl):S10–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469376/

X. Jain M, Singh M. Assisted Reproductive Technology (ART) techniques [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576409/

XI. Elective Single-embryo Transfer (ESET) [Internet]. ReproductiveFacts.org. Available from: https://www.reproductivefacts.org/news-and-publications/fact-sheets-and-infographics/why-would-i-choose-to-have-elective-single-embryo-transfer-eset/

XII. Chamayou S, Giacone F, Cannarella R, Guglielmino A. What does intracytoplasmic sperm injection change in embryonic development? the spermatozoon contribution. Journal of Clinical Medicine [Internet]. 2023 Jan 14;12(2):671. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867417/

XIII. Brown A, McCarthy HE. The Effect of CoQ10 supplementation on ART treatment and oocyte quality in older women. Human Fertility [Internet]. 2023 Apr 27;26(6):1544–52. Available from: https://pubmed.ncbi.nlm.nih.gov/37102567/

XIV. Singh K, Dewani D. Recent advancements in in vitro fertilisation. Cureus [Internet]. 2022 Oct 10; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644046/

XV. Guahmich NL, Borini E, Zaninović N. Improving outcomes of assisted reproductive technologies using artificial intelligence for sperm selection. Fertility and Sterility [Internet]. 2023 Oct 1;120(4):729–34. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0015028223005976

XVI. Gracia CR, Chang J, Kondapalli LA, Prewitt M, Carlson CA, Mattei P, et al. Ovarian tissue cryopreservation for fertility preservation in cancer patients: Successful establishment and feasibility of a multidisciplinary collaboration. Journal of Assisted Reproduction and Genetics [Internet]. 2012 Apr 1;29(6):495–502. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370042/

XVII. Lescano S. (Methods in Molecular Biology 1257) Willem F. Wolkers, Harriëtte Oldenhof (Eds.)-Cryopreservation and Freeze-Drying Protocols-Springer-Verlag New York (2015) (1) [Internet]. Scribd. Available from: https://www.scribd.com/document/357414537/Methods-in-Molecular-Biology-1257-Willem-F-Wolkers-Harriette-Oldenhof-Eds-Cryopreservation-and-Freeze-Drying-Protocols-Springer-Verlag-New-York

XVIII. Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis. Scientific Reports [Internet]. 2017 Aug 17;7(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561141/

XIX. Prasath EB. Ovarian tissue cryopreservation: An update. Journal of Human Reproductive Sciences [Internet]. 2008 Jan 1;1(2):50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700672/

XX. Marcantonini G, Bartolini D, Zatini L, Costa S, Passerini M, Rende M, et al. Natural cryoprotective and cytoprotective agents in cryopreservation: A focus on melatonin. Molecules [Internet]. 2022 May 19;27(10):3254. Available from: https://www.mdpi.com/1420-3049/27/10/3254

XXI. Lee S, Cho HW, Kim B, Lee JK, Kim T. The Effectiveness of Anti-Apoptotic Agents to Preserve Primordial Follicles and Prevent Tissue Damage during Ovarian Tissue Cryopreservation and Xenotransplantation. International Journal of Molecular Sciences [Internet]. 2021 Mar 3;22(5):2534. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961474/

XXII. Casciani V, Monseur B, Cimadomo D, Alvero RJ, Rienzi L. Oocyte and embryo cryopreservation in assisted reproductive technology: past achievements and current challenges. Fertility and Sterility [Internet]. 2023 Sep 1;120(3):506–20. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0015028223005939

XXIII. Lee S, Özkavukçu S, Ku SY. Current and future perspectives for improving ovarian tissue cryopreservation and transplantation outcomes for cancer patients. Reproductive Sciences [Internet]. 2021 Mar 31;28(6):1746–58. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144135/

XXIV. Jin Y, Li S, Q Y, Chen T, Liu D. Application of stem cells in regeneration medicine. MedComm [Internet]. 2023 Jun 17;4(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276889/

XXV. Xu M, Shaw G, Murphy M, Barry F. Induced pluripotent stem Cell-Derived mesenchymal stromal cells are functionally and genetically different from bone Marrow-Derived mesenchymal stromal cells. Stem Cells [Internet]. 2019 Mar 6;37(6):754–65. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591688/

XXVI. Ali I, Padhiar AA, Wang T, He L, Chen M, Wu S, et al. Stem Cell-Based therapeutic Strategies for Premature ovarian insufficiency and infertility: A focus on aging. Cells [Internet]. 2022 Nov 22;11(23):3713. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738202/

XXVII. Bodke VV, Burdette JE. Advancements in microfluidic systems for the study of female reproductive biology. Endocrinology [Internet]. 2021 Apr 14;162(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571709/

XXVIII. Ding X, Schimenti JC. Strategies to identify genetic variants causing infertility. Trends in Molecular Medicine [Internet]. 2021 Aug 1;27(8):792–806. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263794/

XXIX. Fertility NI. OVARIAN PRP [Internet]. Nova IVF Fertility. 2023. Available from: https://www.novaivffertility.com/case-study/ovarian-prp

XXX. Chen J, La Roche LATD, Kahlert UD, Isachenko V, Huang H, Hennefründ J, et al. Artificial ovary for young female breast cancer patients. Frontiers in Medicine [Internet]. 2022 Mar 17;9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969104/